GT
BIOPHARMA, INC.
9350
Wilshire Blvd.
Suite
203
Beverly Hills, CA
90212
February
8, 2021
|
Via EDGAR Submission
|
|
|
|
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100 F
Street, N.E.
Washington,
D.C. 20549
Attention: Tim
Buchmiller
|
|
|
Registration
Statement on Form S-1
CIK No.
0000109657
SEC
Registration No. 333-251311
Ladies
and Gentlemen:
In
accordance with Rule 461 of Regulation C of the General Rules and
Regulations under the Securities Act of 1933, as amended, we hereby
request acceleration of the effective date of the Registration
Statement on Form S-1 (File No. 333-251311) (the
“Registration
Statement”) of GT Biopharma, Inc. (the
“Company”). We
respectfully request that the Registration Statement become
effective as of 5:00 p.m., Eastern Time, on February 10, 2021, or
as soon as practicable thereafter. Once the Registration Statement
has been declared effective, please orally confirm that event with
our counsel, Baker & McKenzie LLP by calling Roger Bivans at
(214) 978-3095.
Thank
you for your assistance with this matter.
|
Very
truly yours,
|
|
/s/
Michael Handelman
|
|
Michael
Handelman
Chief
Financial Officer
|
Click here to enter Sender1 Email Address.
|
|